Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;35(2):632-634.
doi: 10.1038/s41375-020-01015-1. Epub 2020 Aug 7.

Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time

Chiara Cattaneo  1 , Chiara Pagani  2 , Valeria Cancelli  2 , Luisa Imberti  3 , Aldo M Roccaro  4 , Luigi D Notarangelo  5 , Giuseppe Rossi  2
Affiliations

Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time

Chiara Cattaneo et al. Leukemia. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

L.I. has received speaker honoraria from Biogen, Genzyme-Sanofi, Meck-Serono and Novartis, has participated to scientific advisory board for Biogen and has received research funding from FISM Fondazione Italiana Sclerosi Multipla) and research support from Genzyme-Sanofi; A.M.R. reports grants from Associazione Italiana per la Ricerca sul Cancro, European Haematology Association, Fondazione Regionale per la Ricerca Biomedica, ERA-NET TRANSCAN-2, AstraZeneca, and other grants from Amgen, Celgene and Janssen, outside the submitted work; G.R. reports personal fees outside the submitted work from Celgene, Abbvie, Janssen, Jazz, Astellas, Daichii-Sankyo, Amgen and Roche Pfizer. All other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1. Survival of the three cohorts as of June 2nd.
Survival of patients after acute COVID-19 diagnosed in March (formula image), April (formula image) or May 2020 (formula image), respectively. Survival duration was calculated from the date of SARS-CoV-2-positive swab. The difference of survival probability between patients diagnosed in March versus April 2020 is significant (log-rank test: P = 0.03).
See this image and copyright information in PMC

References

    1. von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, Hirsch HH, EHA Infectious Disease Scientific Working Group Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Version 2. Leukemia. 2020;34:1487–94. doi: 10.1038/s41375-020-0832-y. - DOI - PMC - PubMed
    1. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. COVID-19 in persons with haematological cancers. Leukemia. 2020 doi: 10.1038/s41375-020-0836-7. - DOI - PMC - PubMed
    1. Ferrara F, Zappasodi P, Roncoroni E, Borlenghi E, Rossi G. Impact of Covid-19 on the treatment of acute myeloid leukemia. Leukemia. 2020 doi: 10.1038/s41375-020-0925-7. - DOI - PMC - PubMed
    1. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 doi: 10.1158/2159-8290. - DOI - PMC - PubMed
    1. Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with haematological disease. Bone Marrow Transplant. 2020 doi: 10.1038/s41409-020-0931-4. - DOI - PMC - PubMed

Publication types